Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
Stéphane Champiat(The University of Texas MD Anderson Cancer Center), Aurélien Marabelle(Institut Gustave Roussy), Arnaud François(Université de Rouen Normandie), Jean‐Charles Soria(Inserm), Eléonora De Martin(Université Paris-Saclay), Franck Carbonnel(Université Paris-Saclay), A. Berdelou(Université Paris-Sud), S. Feuillet(Université Paris-Sud), Stéphane Éderhy, Rakiba Belkhir(Assistance Publique – Hôpitaux de Paris), Alexander M.M. Eggermont(University Medical Center Utrecht), Didier Samuel(Hôpital Paul-Brousse), Jean‐Marie Michot(Institut Gustave Roussy), Olivier Lambotte(Inserm), Caroline Robert(Institut Gustave Roussy), Michael Collins(Université Paris-Saclay), Julien Lazarovici(Institut Gustave Roussy), Cécile Cauquil(Bicêtre Hospital), Antoine Dürrbach(Inserm), P. Chanson(Inserm), Jérôme Le Pavec(Hôpital Marie Lannelongue), Emmanuel Barreau(Bicêtre Hospital), Christine Mateus(Centre National de la Recherche Scientifique)
Cited by 897
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k